{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-009078","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2022-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.179140+00:00","generated_at":"2026-06-26T09:35:34.194070+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Provectus eliminates Series B Preferred Stock, increases Series D-1 authorized shares","bullets":["Filed Certificate of Elimination for Series B Convertible Preferred Stock; all shares converted to common on Aug 25, 2021.","Filed Certificate of Amendment increasing authorized Series D-1 Preferred Stock from 9,441,000 to 11,241,000 shares.","Both actions effective March 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-009078","json":"https://secwatch.observer/filing/0001493152-22-009078.json","markdown":"https://secwatch.observer/filing/0001493152-22-009078.md","text":"https://secwatch.observer/filing/0001493152-22-009078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315222009078/0001493152-22-009078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315222009078/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T09:35:34.194070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}